



ASX Announcement

19 July 2021



AnteoTech Signs Key South-East Asian Distribution Agreement for EuGeni

Highlights

- ❖ AnteoTech signs first multi-territory EuGeni Distribution Agreement with Biomed Global.
- ❖ Biomed to be the exclusive distributor in Malaysia, Singapore, Indonesia, Vietnam, Thailand, and Myanmar covering a population of 340 million people.
- ❖ Biomed to market and rollout EuGeni readers which will underpin the EuGeni test suite deployment strategy and execute the regulatory requirements for market entry into the six territories.
- ❖ AnteoTech currently conducting a prospective clinical evaluation to assess and confirm the efficacy of different sample specimens as an alternative to the current nasopharyngeal protocol.

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to announce the signing of a Distribution Agreement (Agreement) with Biomed Global Sdn. Bhd (Biomed) and its subsidiaries for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).

The signing of the Agreement concludes an extensive engagement and negotiation period with Biomed, which commenced shortly after AnteoTech obtained European CE Mark registration in April 2021. During this period, both parties conducted due diligence, with Biomed undertaking product evaluation of the EuGeni Reader and the COVID-19 RDT¹ and a market assessment for the regions in which they operate.

Biomed Global is one of the most respected brands in the biomedical and life sciences industry in Malaysia and Singapore. Founded over 20 years ago, Biomed employs over 200 experts, providing innovative technologies in the clinical diagnostics and life science research sector.

Biomed as the authorised representative, distributor and importer for the territories in which they have been appointed, will be responsible for executing the necessary registration to the local medical device authorities to enable sales of the EuGeni reader and tests. AnteoTech will support Biomed with the relevant documentation and data required.

¹ The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19

Key terms of the Agreement are:

- The Agreement became binding on execution.
- Territories: The Agreement is for exclusive sales into Malaysia, Singapore, Indonesia, Vietnam, Thailand, Myanmar.
- Initial 1-year Agreement: The initial term of the distribution agreement is for a period of one year, extendable by an additional two years on mutual agreement.
- Government or large enterprise tender opportunities: AnteoTech and Biomed will work together to assess each tender opportunity on a case-by-case basis.
- In addition to the terms and conditions outlined in the announcement, the Agreement is subject to the standard terms, conditions, and warranties typical of a contract of this type. AnteoTech has the right to terminate the Agreement with immediate effect upon the breach of a number of conditions.

AnteoTech has sufficient test kit manufacturing capacity from its contract manufacturer Operon, in Spain, to meet immediate demand. Further demand is expected to be met by AnteoTech's internal manufacturing capacity, which is being developed.²

AnteoTech is currently negotiating further distribution agreements for additional territories and anticipates updating the market on these discussions in the coming weeks.

AnteoTech CEO Derek Thomson said, "This is a significant milestone for the rollout of the EuGeni Platform signing our first multi-territory agreement. We are delighted to be working with Biomed; they have a strong market presence in South-East Asia and are a well-known and trusted distributor of diagnostic solutions. This agreement will provide us access to six major South-East Asian territories, covering a total population of around 340 million people.

While EuGeni will be a new brand in these countries, rapid diagnostics is an enormous and growing market as we have witnessed over the past 18 months. Biomed will drive sales of the EuGeni platform into laboratories, hospitals and major testing centres, supporting our strategy of deploying EuGeni readers, which can then be utilised with the pipeline of tests in development. Asian borders are starting to open up, and this process requires rapid testing to ensure transiting people are not transmitting COVID-19. We will work with Biomed closely to offer EuGeni as a COVID-19 screening tool to ensure we maximise the potential of these opportunities."

Sample Use Case Validation Ongoing

As previously advised,³ AnteoTech has been evaluating the possibility of detecting the SARS-CoV-2 antigen taken from sample sites offering a more comfortable method of testing for the patient. The initial evaluation was conducted with stored saliva spit samples obtained in the UK. The outcome of this work indicated a need to further evaluate the test utilising real patient samples within the format of a prospective clinical evaluation. Following strong interest in the EuGeni platform and COVID-19 RDT from a number of Indian companies, the opportunity to conduct an extensive prospective clinical evaluation arose, allowing us to further assess the performance of the EuGeni COVID-19 RDT using live patient samples.

In collaboration with a potential distribution partner in India, AnteoTech commenced a prospective clinical evaluation in June to evaluate the efficacy of different sample specimens as an alternative to


² ASX 24 May 20201 – EuGeni Test Strip Manufacturing Strategy

³ ASX 30 April 2021 – Quarterly Activities Report - Period Ending 31 March 2021

the current nasopharyngeal protocol. This includes efficacy testing of saliva samples from the oral mucosa, oropharyngeal throat samples and mid-turbinate nasal samples for the detection of SARS-CoV-2 antigen. Patient comfort and ease of sampling for clinicians is an important aspect of the EuGeni COVID-19 RDT test design, as testing comfort may lead to increased voluntary testing and compliance with public health orders.

AnteoTech anticipated results from the evaluation in line with the initially indicated timeline of June 2021; however, the significant decrease of COVID-19 incidents in India has meant this is likely to take several more weeks to obtain sufficient data to evaluate the efficacy. The timing of results and further updates to shareholders will be dependent on obtaining enough positive samples to clearly evaluate the test. Shareholders will be advised of the finalisation of the approach to update CE Mark when the Company has material information at hand to update the market via ASX Announcements.

Oropharyngeal throat and mid turbinate nasal samples



Oropharyngeal sampling involves the swabbing and collection of epithelial cells from the tonsillar beds and the back of the throat, avoiding the tongue.⁴



Mid-turbinate samples are collected by inserting and gently rotating a swab about 2 cm into nostril parallel to the palate (not upwards) until resistance is met.⁵

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT BIOMED

Biomed Global is one of the most respected brands in the biomedical and life sciences industry in Malaysia and Singapore. Their journey began over two decades ago driven by our passion to make a difference to doctors, patients, researchers and academics. Today Biomed are a team comprising nearly 200 experts representing some of the world's renowned brands in the biomedical and life sciences industry. Biomed are admired by the industry for their expertise, speed, commitment and market knowledge. <https://www.biomed-global.com/en/>

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.



Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit www.anteotech.com

⁴ ASM Journals Journal of Clinical Microbiology Vol. 53, No. 2 Equal Performance of Self-Collected and Health Care Worker-Collected Pharyngeal Swabs for Group A Streptococcus Testing by PCR

⁵ CDC Nasal mid turbinate specimen collection steps PDF.